+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID06625177

Safety and Exploratory Efficacy Study of TEV-53408 Injection for Adults With Vitiligo

Led by Teva Branded Pharmaceutical Products R&D LLC · Updated on 2026-10-29

66

Participants Needed

13

Research Sites

40 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety of TEV-53408, given as an under the skin injection, in adults with vitiligo, a condition where patches of skin lose color and turn white. The study is a phase 1b, open-label trial conducted to explore both safety and early signs of how the treatment works in this population. Participants will receive one of several doses of TEV-53408 through subcutaneous injections. The study includes different cohorts receiving different doses, and it follows participants for up to 40 weeks to monitor treatment effects and safety. The trial focuses on recording any adverse events, including serious or treatment-related issues, as well as treatment discontinuations due to side effects. After this period, additional monitoring for specific adverse events continues up to 80 weeks. Throughout the study, participants will be closely monitored with regular assessments for safety, including tracking any side effects and adverse events. Researchers will measure how many participants experience treatment-related problems and those who stop treatment because of side effects. The study requires participants to avoid other treatments for vitiligo during the trial and to use sun protection measures. The total involvement can last up to about 80 weeks, including follow-up periods for safety evaluation.

CONDITIONS

Brief Title

A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo

Research Team

T

Teva U.S. Medical Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here